GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » Pretax Margin %

Acura Pharmaceuticals (Acura Pharmaceuticals) Pretax Margin % : 80.56% (As of Dec. 2021)


View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Acura Pharmaceuticals's Pre-Tax Income for the three months ended in Dec. 2021 was $0.03 Mil. Acura Pharmaceuticals's Revenue for the three months ended in Dec. 2021 was $0.04 Mil. Therefore, Acura Pharmaceuticals's pretax margin for the quarter that ended in Dec. 2021 was 80.56%.

The historical rank and industry rank for Acura Pharmaceuticals's Pretax Margin % or its related term are showing as below:


ACUR's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 4.555
* Ranked among companies with meaningful Pretax Margin % only.

Acura Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Acura Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acura Pharmaceuticals Pretax Margin % Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -196.12 -937.07 -142.04 -33.84 -56.24

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.84 -40.22 -63.13 -97.04 80.56

Competitive Comparison of Acura Pharmaceuticals's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acura Pharmaceuticals's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's Pretax Margin % falls into.



Acura Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Acura Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2021 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-0.879/1.563
=-56.24 %

Acura Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2021 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2021 )/Revenue (Q: Dec. 2021 )
=0.029/0.036
=80.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acura Pharmaceuticals  (OTCPK:ACUR) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Acura Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.
Executives
Bruce F Wesson director 1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly director C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross director 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh officer: VP, Corporate Development
Immanuel Thangaraj director 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser officer: VP, Treasurer & Controller C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones officer: President & CEO C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko officer: VP Pharmaceutical Sciences APT C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens officer: Senior VP & CFO C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc 10 percent owner 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc 10 percent owner C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte 10 percent owner 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P 10 percent owner 610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc 10 percent owner 680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp 10 percent owner 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020

Acura Pharmaceuticals (Acura Pharmaceuticals) Headlines

From GuruFocus

Acura Pharmaceuticals Announces Conversion of Debt

By Marketwired Marketwired 06-14-2021

Acura Pharmaceuticals Provides Development Update on LTX-03

By Marketwired Marketwired 06-07-2021

Acura Pharmaceuticals Licenses LIMITx™ LTX-03

By Marketwired Marketwired 07-03-2019

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx� LTX-03

By GuruFocusNews GuruFocusNews 03-01-2022